ATE483473T1 - Verwendung von antikörpern in einer sehr geringen dosis zur impfung gegen krebs - Google Patents

Verwendung von antikörpern in einer sehr geringen dosis zur impfung gegen krebs

Info

Publication number
ATE483473T1
ATE483473T1 AT04450149T AT04450149T ATE483473T1 AT E483473 T1 ATE483473 T1 AT E483473T1 AT 04450149 T AT04450149 T AT 04450149T AT 04450149 T AT04450149 T AT 04450149T AT E483473 T1 ATE483473 T1 AT E483473T1
Authority
AT
Austria
Prior art keywords
antibodies
against cancer
low dose
vaccinate against
antibody
Prior art date
Application number
AT04450149T
Other languages
English (en)
Inventor
Hans Loibner
Gottfried Himmler
Manfred Schuster
Original Assignee
Altropus Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34933149&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE483473(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Altropus Gmbh filed Critical Altropus Gmbh
Application granted granted Critical
Publication of ATE483473T1 publication Critical patent/ATE483473T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT04450149T 2004-07-20 2004-07-20 Verwendung von antikörpern in einer sehr geringen dosis zur impfung gegen krebs ATE483473T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04450149A EP1618890B1 (de) 2004-07-20 2004-07-20 Verwendung von Antikörpern in einer sehr geringen Dosis zur Impfung gegen Krebs

Publications (1)

Publication Number Publication Date
ATE483473T1 true ATE483473T1 (de) 2010-10-15

Family

ID=34933149

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04450149T ATE483473T1 (de) 2004-07-20 2004-07-20 Verwendung von antikörpern in einer sehr geringen dosis zur impfung gegen krebs

Country Status (4)

Country Link
US (1) US20060018901A1 (de)
EP (1) EP1618890B1 (de)
AT (1) ATE483473T1 (de)
DE (1) DE602004029455D1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2041181B1 (de) * 2006-06-08 2011-05-18 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Spezifische proteaseinhibitoren und ihre verwendung in der krebstherapie
WO2011063133A1 (en) * 2009-11-18 2011-05-26 Auburn University LOW ANTIGEN-DOSE IMMUNIZATION FOR MAXIMIZING T-HELPER CELL 1 (T h1) IMMUNITY AGAINST DISEASE
JP6216301B2 (ja) 2014-09-19 2017-10-18 ミネベアミツミ株式会社 照明装置

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144265A0 (en) * 1999-01-13 2002-05-23 Igeneon Gmbh Use of antibodies for the vaccination against cancer

Also Published As

Publication number Publication date
US20060018901A1 (en) 2006-01-26
DE602004029455D1 (de) 2010-11-18
EP1618890B1 (de) 2010-10-06
EP1618890A1 (de) 2006-01-25

Similar Documents

Publication Publication Date Title
DK1734995T3 (da) Monoklonale antistoffer og hepatocyytvækstfaktor
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
DK1572748T3 (da) Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2
AR069903A1 (es) Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer
DE60138641D1 (de) Herstellung von mikrokügelchen
WO2007115049A3 (en) Humanized monoclonal antibodies to hepatocyte growth factor
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
ZA200702879B (en) Single domain antibodies against TNFR1 and methods of use therefor
NZ600143A (en) Therapeutic applications of activation of human antigen-presenting cells through dectin-1
DE50000243D1 (de) Verwendung von antikörpern zur vakzinierung gegen krebs
ATE528319T1 (de) Krebsbehandlung mit anti-il-1-antikörpern
TW200624479A (en) Film forming material and preparation of surface relief and optically anisotropic structures by irradiating a film of the said material
DE60217698D1 (de) Behandlung chronischer gelenkentzündung unter verwendung eines antikörpers gegen das cd3 antigenkomplex
DE602004024902D1 (de) Verbesserte formulierung zur bereitstellung eines magensaftresitenten beschichtungsmaterials
NO20012135L (no) Forsterkede vaksiner
ATE483473T1 (de) Verwendung von antikörpern in einer sehr geringen dosis zur impfung gegen krebs
DE112005001260A5 (de) Antigen des PM-2 Antikörpers und dessen Verwendung
AR055072A1 (es) Uso de anticuerpos anti- madcam para el tratamiento de enfermedad celiaca y esprue tropical
ATE526035T1 (de) Tollwut-impfstoff
ATE552839T1 (de) Pharmazeutische verwendung von immunologisch mit diphtherie-toxin korrelierten proteinmolekülen
TR201902670T4 (tr) Anti-5t4 antikorları ve bunların kullanımları.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1618890

Country of ref document: EP